- |||||||||| Leukine (sargramostim) / Partner Therap
Enrollment open: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - Mar 25, 2017 P2, N=15, Recruiting, Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- |||||||||| Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion, Surgery: Surgery in Treating Children With Neuroblastoma (clinicaltrials.gov) - Mar 13, 2017 P3, N=968, Completed, Recruiting --> Suspended Active, not recruiting --> Completed
- |||||||||| Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed, Trial initiation date: Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (clinicaltrials.gov) - Mar 9, 2017 P2, N=25, Active, not recruiting, Trial primary completion date: Sep 2017 --> Sep 2018 Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Nov 2015
- |||||||||| SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion, Trial primary completion date: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Feb 27, 2017 P1, N=9, Completed, N=10 --> 2 | Active, not recruiting --> Terminated; Slow Accrual Trial primary completion date: May 2017 --> May 2014 | Active, not recruiting --> Completed
- |||||||||| NeuVax (nelipepimut-S) / Dr. Reddy's
Trial completion, Trial primary completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - Feb 24, 2017 P3, N=700, Completed, Trial primary completion date: Nov 2017 --> Nov 2018 Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2016
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Trial primary completion date: Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 23, 2017 P2/3, N=60, Recruiting, Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2016 Trial primary completion date: Jan 2017 --> Dec 2019
- |||||||||| Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date, Combination therapy: Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 17, 2017 P2, N=119, Completed, Trial primary completion date: Jan 2017 --> Dec 2019 Active, not recruiting --> Completed | Trial primary completion date: Aug 2018 --> Jan 2017
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment change, Trial termination, Trial primary completion date: NB2013-HR German (GPOH) / Dutch (DCOG) Trial (clinicaltrials.gov) - Feb 2, 2017 P2, N=3, Terminated, Trial primary completion date: Aug 2017 --> Aug 2018 N=36 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Dec 2016; Antibody supply was discontinued by United Therapeutics Corporation.
- |||||||||| Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 30, 2017 P1, N=51, Active, not recruiting, N=36 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Dec 2016; Antibody supply was discontinued by United Therapeutics Corporation. Trial primary completion date: Jan 2017 --> Jan 2018
- |||||||||| Leukine (sargramostim) / Partner Therap
Trial primary completion date: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - Jan 26, 2017 P2, N=40, Recruiting, Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Dec 2016 --> Nov 2017
- |||||||||| UV1 / Ultimovacs
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (clinicaltrials.gov) - Jan 26, 2017 P1/2, N=12, Active, not recruiting, Trial primary completion date: Dec 2016 --> Nov 2017 Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Nov 2016 --> Nov 2019
- |||||||||| Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Trial primary completion date: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Jan 4, 2017 P2, N=300, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion, Trial primary completion date: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Dec 2, 2016 P3, N=1449, Completed, Trial primary completion date: Feb 2008 --> Jul 2003 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2012
- |||||||||| Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma (clinicaltrials.gov) - Nov 7, 2016 P2, N=52, Completed, Initiation date: Jan 2017 --> Jul 2017 | Trial primary completion date: Jan 2022 --> Jul 2022 Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Nov 2016
- |||||||||| SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment closed, Trial primary completion date: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Nov 2, 2016 P1, N=9, Active, not recruiting, Trial primary completion date: Jul 2015 --> Jul 2020 Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017
|